Prudential Financial’s LogicBio Therapeutics LOGC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-98,600
Closed -$27K – 2748
2022
Q3
$27K Buy
98,600
+34,600
+54% +$13.7K ﹤0.01% 2616
2022
Q2
$23K Buy
+64,000
New +$32.4K ﹤0.01% 2642

Prudential Financial's LOGC Position: Q4 2022 in Review

Prudential Financial sold out of LogicBio Therapeutics (LOGC) in Q4 2022, closing a stake of 98,600 shares — an estimated $27K sold.

Prudential Financial first reported a position in LOGC in Q2 2022 and held it in 2 quarters. The position peaked at $27K in Q3 2022. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

  • Prudential Financial reported no remaining LogicBio Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Prudential Financial sold 98,600 LogicBio Therapeutics shares in Q4 2022, an estimated $27K.
  • Prudential Financial first reported a position in LogicBio Therapeutics in Q2 2022 and held it in 2 quarters.
  • Prudential Financial's LogicBio Therapeutics position peaked at $27K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held LogicBio Therapeutics as of Q4 2022.

Based on Prudential Financial's 13F filing for Q4 2022, filed 14 Feb 2023.